N-(pyridin-2-yl)-5-nitrofuran-2-carboxamide | 14121-87-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: N-(pyridin-2-yl)-5-nitrofuran-2-carboxamide
• 英文别名: 5-nitro-furan-2-carboxylic acid pyridin-2-ylamide；5-nitro-N-(2-pyridyl)furan-2-carboxamide；5-nitro-N-pyridin-2-ylfuran-2-carboxamide
• CAS: 14121-87-0
• 化学式: C₁₀H₇N₃O₄
• 分子量: 233.183
• InChiKey: BUQOMEXWMPHRPO-UHFFFAOYSA-N

物化性质

• 沸点：
  322.1±32.0 °C(Predicted)
• 密度：
  1.493±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(pyridin-2-yl)-5-nitrofuran-2-carboxamide 生成 2-[5-(5-nitro-furan-2-yl)-tetrazol-1-yl]-pyridine
  参考文献：
  名称：

  Nitrofuryl Heterocycles. VI.¹ l-Alkyl-and l-Aryl-5-(5-nitro-2-furyl)tetrazoles

  摘要：

  DOI：

  10.1021/jm00316a052
• 作为产物：
  描述：

  5-硝基-2-糠酸 在 4-二甲氨基吡啶 、 草酰氯 、 N,N-二异丙基乙胺 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 生成 N-(pyridin-2-yl)-5-nitrofuran-2-carboxamide
  参考文献：
  名称：

  Synthesis and Evaluation of Nitrofuranylamides as Novel Antituberculosis Agents

  摘要：

  In an effort to develop new and more potent therapies to treat tuberculosis, a library of compounds was screened for M. tuberculosis UDP-Gal mutase inhibition. Nitrofuranylamide 1 was identified as a hit in this screen, possessing good antituberculosis activity. This paper describes the synthesis and evaluation of an expanded set of nitrofaranylamides. We have discovered a number of nitrofaranylamides with submicromolar M. tuberculosis MIC values and acceptable therapeutic indexes. The MIC activity did not correlate with UDP-Gal mutase inhibition, suggesting an alternative primary cellular target was responsible for the antituberculosis activity. The compounds were only active against mycobacteria of the tuberculosis complex. On the basis of these results, four compounds were selected for in vivo testing in a mouse model of tuberculosis infection, and of these compounds one showed significant antituberculosis activity.

  DOI：

  10.1021/jm049972y

文献信息

• 二芳基酰胺类化合物及其应用
  申请人：北京龙嘉博创医药科技有限公司

  公开号：CN112107568B

  公开（公告）日：2022-03-25

  本发明公开了具有式(I)所示结构的二芳基酰胺类化合物、其药学上可接受的盐在制备作为尿素通道蛋白抑制剂的药物中的用途以及一类新型的二芳基酰胺类化合物，本发明的二芳基酰胺类化合物具有良好的尿素通道蛋白抑制剂作用，能够在体内产生尿素选择性利尿并且没有明显的毒性作用。
• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。
• DIARYLAMIDE COMPOUND AND APPLICATION THEREOF
  申请人：Peking University

  公开号：EP3984534A1

  公开（公告）日：2022-04-20

  A use of a diarylamide compound having the structure as shown in formula (I) or a pharmaceutically acceptable salt thereof in preparing a drug which acts as a urea transporter protein inhibitor, and a novel diarylamide compound. The diarylamide compound has urea transporter protein inhibitor effect, and can produce urea selective diuresis in the body without obvious toxicity.

  一种具有式（I）所示结构的二芳基酰胺化合物或其药学上可接受的盐在制备作为尿素转运蛋白抑制剂的药物中的用途，以及一种新型二芳基酰胺化合物。该二芳基酰胺化合物具有尿素转运蛋白抑制剂的作用，可在体内产生尿素选择性利尿作用，且无明显毒性。
• [EN] DIARYLAMIDE COMPOUND AND APPLICATION THEREOF<br/>[FR] COMPOSÉ DE DIARYLAMIDE ET SON APPLICATION<br/>[ZH] 二芳基酰胺类化合物及其应用
  申请人：UNIV BEIJING

  公开号：WO2020253802A1

  公开（公告）日：2020-12-24

  具有式(I)所示结构的二芳基酰胺类化合物、其药学上可接受的盐在制备作为尿素通道蛋白抑制剂的药物中的用途以及一类新型的二芳基酰胺类化合物，所述二芳基酰胺类化合物具有尿素通道蛋白抑制剂作用，能够在体内产生尿素选择性利尿并且没有明显的毒性作用。
• Synthesis and Evaluation of Nitrofuranylamides as Novel Antituberculosis Agents
  作者：Rajendra P. Tangallapally、Raghunandan Yendapally、Robin E. Lee、Kirk Hevener、Victoria C. Jones、Anne J. M. Lenaerts、Michael R. McNeil、Yuehong Wang、Scott Franzblau、Richard E. Lee

  DOI：10.1021/jm049972y

  日期：2004.10.1

  In an effort to develop new and more potent therapies to treat tuberculosis, a library of compounds was screened for M. tuberculosis UDP-Gal mutase inhibition. Nitrofuranylamide 1 was identified as a hit in this screen, possessing good antituberculosis activity. This paper describes the synthesis and evaluation of an expanded set of nitrofaranylamides. We have discovered a number of nitrofaranylamides with submicromolar M. tuberculosis MIC values and acceptable therapeutic indexes. The MIC activity did not correlate with UDP-Gal mutase inhibition, suggesting an alternative primary cellular target was responsible for the antituberculosis activity. The compounds were only active against mycobacteria of the tuberculosis complex. On the basis of these results, four compounds were selected for in vivo testing in a mouse model of tuberculosis infection, and of these compounds one showed significant antituberculosis activity.